Drug intelligence / Profile preview

FFT-105

Development stage: Preclinical
Lead developer: F5 Therapeutics
Modality: Targeted Protein Degraders (TPDs) → Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules

Overview

FFT-105 is a drug candidate under development by F5 Therapeutics, Inc. It is being investigated for therapeutic applications in Neoplasms (cancers) and Liver Fibrosis. The drug leverages advanced technology platforms such as degrader-antibody conjugates and degradable molecular glues, which are designed to induce the degradation of specific disease-causing proteins.

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on FFT-105.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FFT-105.

Explore the full profile